CHRD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Chord Energy looks like a good long-term buy for a beginner with $50,000-$100,000 available, but it is not an aggressive momentum buy. My direct view: BUY. The stock has supportive fundamentals, improving analyst targets, strong free cash flow, and a favorable options sentiment backdrop. The technical setup is mixed in the very short term, so the best read is that this is a reasonable entry for a long-term investor who wants exposure now rather than waiting for a perfect pullback.
CHRD is in a constructive intermediate uptrend because the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, near-term momentum has softened: MACD histogram is slightly negative and expanding, and RSI_6 at 39.0 shows the stock is not overbought but also not strongly trending up right now. Price at 138.73 is below the pivot at 142.01 and above support at 135.25, which suggests the stock is sitting in a buyable zone but not yet in a breakout position. The recent pattern implies limited immediate upside over the next day or week, but the one-month expectation is mildly positive.
Recent Q1 2026 results were strong on cash generation: adjusted free cash flow of $324 million beat expectations, free cash flow was $321.2 million, and revenue rose 37.08% YoY. The company also raised its 2026 oil volume outlook by 2,000 barrels per day and is targeting about $1.4 billion in free cash flow at $80 oil. Shareholder returns remain solid, with $145 million returned in Q1 via dividends and buybacks, plus a base dividend of $1.30 per share. Analyst sentiment is broadly favorable, with multiple firms raising price targets and several Buy/Outperform/Overweight ratings.
Net income fell 50.32% YoY and EPS dropped 47.81% YoY, so profitability is under pressure despite revenue growth. Gross margin also declined sharply by 28.08% YoY. Technically, MACD is negative and short-term price momentum is weak. The market’s short-term candlestick pattern forecast is soft over the next week. Hedge funds and insiders are both neutral, so there is no strong ownership-based catalyst. No recent congress trading data is available.
In Q1 2026, CHRD showed strong top-line growth with revenue up 37.08% YoY to 1.666B, and operationally it outperformed on production and free cash flow. The latest quarter season is Q1 2026. However, earnings quality weakened: net income fell to 108.6M, EPS dropped to 1.91, and gross margin compressed to 26.41. Overall, the quarter was good for cash flow and production, but weaker on bottom-line profitability.
Analyst sentiment has turned more constructive over the past month. UBS raised its target to 179 and kept Buy, Mizuho raised to 164 and kept Outperform, BofA raised to 165 and kept Buy, Siebert Williams raised to 189 and kept Buy, Wells Fargo raised to 175 and kept Overweight, and Morgan Stanley upgraded to Overweight with a 168 target. Citi remains more cautious with Neutral despite raising its target to 155, and Scotiabank is Sector Perform with a 135 target. Wall Street’s pros: strong capital discipline, shareholder returns, compelling valuation, and healthy free cash flow. Cons: some firms see only limited near-term production upside and sector sensitivity to oil price moves.
